ArticleChinese medicine2026
A stabilized enrichment method for rosemary diterpenoids and their therapeutic potential in diabetic kidney disease.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAs a traditional medicinal herb, rosemary leaves have shown potential for the treatment for diabetic kidney disease (DKD). However, the bioactive compounds responsible for its anti-DKD effects remain unidentified, and the instability of its primary phytochemicals limits its practical application.
methodsThis study investigated the active components of rosemary leaves and characterized their degradation pathways using UPLC-Q/TOF-MS/MS. Four solvent-extracted fractions were evaluated using an in vitro DKD model to identify the major anti-DKD constituents. A targeted enrichment method was then developed to isolate these bioactive compounds. Finally, a DKD model was established in C57BL/6J mice using high-fat diet combined with streptozotocin injection to evaluate the therapeutic effects of the enriched extracts. The pharmacokinetic profiles of the major components of TD were further investigated.
results38 chemical constituents were characterized with diterpenoids were identified as the primary anti-DKD constituents by in vitro DKD model. Considering their pronounced susceptibility to oxidative degradation, a novel enrichment strategy for total diterpenoids (TD) was developed based on water and ethanol. Vitamin C served as a stabilizer to improve TD stability, leading to a TD extraction yield of 40.12% and the diterpenoid content of 81.80%. In vivo studies revealed that TD attenuated renal injury, improved glucose and lipid dysmetabolism, and reduced renal oxidative stress in DKD mice. The in vivo absorption profiles showed that TD also exhibited good bioavailability.
conclusionThis study provides an effective method for TD enrichment and demonstrates the renoprotective effects of TD. These findings offer new insights on the broader use of rosemary leaves and the development of natural product-based therapies for DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.